Daily Equity Report 31 JULY 2019

1. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647 DAILY EQUITY REPORT 31 STJULY 2019 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

2. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report INDIAN FACE INDIAN MARKET CLOSE PREVIOUS ! 37686.37 INDIAN EQUITY BENCHMARK - Nifty ends below 11,100, Sensex falls 289 pts; PSU banks tumble 5%, Bharti Airtel up 3% At close, the Sensex was down 289.13 points at NIFTY 11189.20 37,397.24, while Nifty was down 103.80 points at 11,085.40. CLOSE PREVIOUS Indices fell for the second consecutive day on July 30 with NIKKEI 21616.80 Nifty ended below 11,100 level on the back of selling in PSU banks, metal and auto. At close, the Sensex was down 289.13 28106.41 points at 37,397.24, while Nifty was down 103.80 points at 2038.68 2029.48 11,085.40. About 567 shares have advanced, 1907 shares SECTORIAL INDICES declined, and 109 shares are unchanged. Yes Bank, IndusInd CLOSE Bank, Indiabulls Housing, Hero Motocorp and Sun Pharma CNX 100 11179.55 -0.99 were among major losers on the Nifty, while gainers were S&P CNX 500 -1.15 Bharti Airtel, TCS, HCL Tech, ITC and HUL. Except IT, all other sectoral indices ended in the red led by PSU bank -2.26 (down 4.9%), metal (down 3.2%), auto (down 2%), pharma CNX 200 -1.08 (down 2%) followed by energy, FMCG and infra. GLOBAL FACE BANK NIFTY 28791.60 -1.72 TOP GAINERS ! CLOSE CHANGE (%) Asian Market - Asian markets finished higher today with shares in Japan leading the region. The Nikkei 225 is up 0.43% while China's Shanghai Composite is up 0.39% and BHARTIARTL Hong Kong's Hang Seng is up 0.17%. ! WIPRO U.S. Market – North and South American markets finished mixed as of the most recent closing prices. The IPC gained TOP LOSERS 1.48% and the Bovespa rose 0.65%. The S&P 500 lost 0.16%. CLOSE CHANGE (%) ! YESBANK European markets – European markets are mixed. The FTSE 100 is higher by 0.07%, while the DAX is leading the CAC 40 lower. They are down 1.74% and 1.05% respectively. INDUSINDBK HEROMOTOCO Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

3. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report NIFTY SPOT MARKET MOVERS UPSIDE STRATEGY SELL ON RISE SCRIPT CLOSE (%) 3.99 BHARTIARTL PIVOT POINTS P 11141 S3 10752 S2 10947 S1 R1 11211 R2 11336 RESISTANCE R1-11250 R2-11360 R3 11531 HDFCBANK 0.47 11016 0.34 SUPPORT S1-11000 S2-10900 TITAN 0.32 CLOSE (%) YESBANK 85.80 SBIN NET BUY (CR.) NET INSTITUTION SELL (CR) FII 4144.16 TREND STRATEGY SELL ON RISE 3292.35 PIVOT POINTS P 29082 SUPPORT NSE TOTALS S2 28295 S1 28576 R2 R3 30656 DECLINE S 27508 29363 29869 RESISTANCE R1-29100 R2-29320 INDICES BANK NIFTY NIFTY 1 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

4. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report ! ! Dr. Reddy's Labs launches Pregabalin capsules in the US ICRA expects some weakening in Retail- NBFC asset quality in the current fiscal The assets under management (AUM) of retail non- banking finance companies grew at a much slower pace of ~9.5% (over September 2018) during H2FY2019 vis a vis ~13% during H2FY2018 (over September 2017) due to tightening of liquidity. Typically, though Retail-NBFC growth in H2 is higher than H1, in FY2019, it was lower than H1 growth of 11.5%. Therefore, overall credit growth of 22% during FY2019 was largely supported by the H1 performance. The Retail-NBFC AUM stood at Rs9.1 trillion as on March 31, 2019. Dr Reddys Laboratories announced the launch of Pregabalin capsules in the US market.Shares of the company are down 2.5%.Pregabalin Capsules is a therapeutic equivalent generic version of Lyrica® (pregabalin) Capsules approved by the US Food and Drug Administration (USFDA). The Lyrica® (pregabalin) Capsules brand had US sales of ~$5,462mn MAT for the most recent twelve months ending in May 2019, according to IQVIA Health. Dr. Reddy's Pregabalin Capsules are available in 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg capsules in bottle count sizes of 90. This is also a controlled substance schedule V product. ! Bank of India stock slumps 6% even as net profit jumps 154% yoy to Rs243cr Shares of Bank of India are down 6% even as its PAT for the quarter ending Jun'19 more than doubled over its year-ago profit. Net profit up 154% at Rs242.6cr vs. Rs 95.1cr yoy. Its net interest income (NII) grew 3.9% yoy at Rs3, 485.4cr against Rs3, 354.3cr in the corresponding period last year.Gross NPA came in at 16.50% and net NPA at 5.79% qoq. ! Dilip Buildcon declared L-1 bidder for Khaki dam construction Dilip Buildcon Limited has been declared L-1 bidder for the project involving construction of Kharkai Dam at Icha with all control gates and its allied works including civil, mechanical (with Design of Gates), electrical and SCADA system under SMP in the state of Jharkhand. The Company has been declared L-1 bidder by the Water Resources Department for the project in the state of Jharkhand. The project cost is Rs972cr, and the completion period is 26 months. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

5. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report NAME OF THE STOCK : BAJAJHLDNG DATE : 31/07/2019 SEGMENT : CASH CHART TYPE : Candlestick EXCHANGE : NSE TECHNICAL INDICATORS USED : VOLUME.MACD,RSI. CHART INVESTMENT ADVICE: CALL CS CALL:- BUY BAJAJHLDNG IN CASH ABOVE 3565 TGT 3630 SL 3500 RATIONALE FOR ARRIVING INVESTMENT ADVICE : TECHNICAL VIEW : THE STOCK TECHINCALLY IS UP ,TAKING SUPPORT OF VOLUME.RESISTANCE IS BROKEN TODAY WITH HEAVY VOLUME.AS WELL AS A POSSIBILITY OF UPWARD MOVEMENT IS THERE. OTHER REASON IF ANY :- SHOWING STRENGTHS IN INTRADAY CHARTS AS WELL Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

6. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. DISCLAIMER The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. CapitalStars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets are always subjected to market risk. CapitalStars Financial Research Private Ltd., Reserves all Rights. INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

7. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market. we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors. we provide intraday as well as delivery stock tips in NSE and BSE and commodity tips in MCX and NCDEX. Get our more services:- Mcx Tips Financial advisory company Sharemarket company Stock Tips Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

8. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. BRANCH OFFICE Capitalstars Financial Research Private Limited PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME NO.54,VIJAYNAGAR INDORE REGISTERED OFFICE PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE Email:-backoffice@capiltalstars.in Contact us :- 9977499927, 9039012727 Report Is Checked by Investment Advisor: Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.